Evidence map›Paper›PMID 39651832›Full record

ArticleActa ophthalmologica2025

Users of reimbursed glaucoma medications in Finland in 1986-2023: A nationwide study.

E Lehtonen, A Tuulonen, S Leinonen, K Vepsäläinen, H Uusitalo-Jarvinen

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

E LehtonenFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
A TuulonenTays Eye Centre, Tampere University Hospital, Tampere, Finland.ORCID https://orcid.org/0000-0003-1077-3691
S LeinonenFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
K VepsäläinenTays Eye Centre, Tampere University Hospital, Tampere, Finland.
H Uusitalo-JarvinenFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID https://orcid.org/0000-0002-2030-295X

Funding

Finnish Eye FoundationLUX - foundation for glaucoma researchState funding for university-level health research, Tampere University Hospital, Wellbeing services county of Pirkanmaa T63464State funding for university-level health research, Tampere University Hospital, Wellbeing services county of Pirkanmaa T64484Tampere University Hospital Support Foundation, Tampere University Hospital, Wellbeing services county of Pirkanmaa T64124
6 · The paper itself

Abstract

purposeThe study evaluates the long-term trends in the number of patients using reimbursed glaucoma medications in Finland.

methodsReimbursement data of 193 082 new glaucoma patients in 1986-2023 were collected from the registry of Finnish Insurance Institution (Kela). The numbers of new, current and deceased users of reimbursed glaucoma medications in Finland at end of each year were analysed by gender and in different age groups.

resultsThe number of glaucoma reimbursees per total Finnish population increased 2.5-fold during 37 years. However, in 2015-2023 the data demonstrated an unexpected decelerating trend in the difference between the number of new and deceased users of glaucoma medications (i.e. 'net change' in the medication users). In addition, differences in glaucoma medication users between Finland, other Nordic countries and Scotland were detected.

conclusionsThe 37-year period demonstrates an overall increasing trend in the number of glaucoma medication reimbursees in Finland. However, the slowing growth in the net change during the recent years is to the contrary to what has generally been forecasted in Finland and globally. Future studies, including an updated prediction model, will be required to clarify whether the number of glaucoma patients under treatment will increase, or decrease in Finland in future as well as to figure out the reasons for the variations.

Indexed as

Antihypertensive AgentsDrug PrescriptionsGlaucomaInsurance, Health, ReimbursementIntraocular PressureRegistriesAdolescentAdultAgedAged, 80 and overFemaleFinlandFollow-Up StudiesHumansMaleMiddle AgedAntihypertensive Agentsglaucomaintraocular pressure lowering medicationslong‐term trendsmedication users

Identifiers

PMID39651832
PMCPMC11986400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.